Redhill Biopharma Company Profile (NASDAQ:RDHL)

About Redhill Biopharma (NASDAQ:RDHL)

Redhill Biopharma logoRedhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools. Its clinical-stage pipeline includes: TALICIA (RHB-105), an oral combination therapy for the treatment of Helicobacter pylori infection; RHB-104, an oral combination therapy for the treatment of Crohn's disease; BEKINDA (RHB-102), a once-daily oral pill formulation of ondansetron; RHB-106; YELIVA (ABC294640); MESUPRON, and RIZAPORT (RHB-103).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:RDHL
  • CUSIP: N/A
  • Web: www.redhillbio.com
Capitalization:
  • Market Cap: $159.83 million
  • Outstanding Shares: 17,007,000
Average Prices:
  • 50 Day Moving Avg: $8.91
  • 200 Day Moving Avg: $9.69
  • 52 Week Range: $8.16 - $16.54
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.20
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $101,000.00
  • Price / Sales: 1,577.78
  • Book Value: $3.47 per share
  • Price / Book: 2.70
Profitability:
  • EBIDTA: ($34,690,000.00)
  • Return on Equity: -61.47%
  • Return on Assets: -52.13%
Debt:
  • Current Ratio: 10.94%
  • Quick Ratio: 10.94%
Misc:
  • Average Volume: 62,165 shs.
  • Beta: 0.54
  • Short Ratio: 3.6
 
Frequently Asked Questions for Redhill Biopharma (NASDAQ:RDHL)

What is Redhill Biopharma's stock symbol?

Redhill Biopharma trades on the NASDAQ under the ticker symbol "RDHL."

How were Redhill Biopharma's earnings last quarter?

Redhill Biopharma Ltd. (NASDAQ:RDHL) announced its quarterly earnings data on Wednesday, May, 3rd. The company reported ($0.50) EPS for the quarter, beating the Zacks' consensus estimate of ($0.64) by $0.14. View Redhill Biopharma's Earnings History.

Where is Redhill Biopharma's stock going? Where will Redhill Biopharma's stock price be in 2017?

3 brokerages have issued 1-year price objectives for Redhill Biopharma's stock. Their predictions range from $25.00 to $33.00. On average, they anticipate Redhill Biopharma's stock price to reach $28.00 in the next twelve months. View Analyst Ratings for Redhill Biopharma.

What are analysts saying about Redhill Biopharma stock?

Here are some recent quotes from research analysts about Redhill Biopharma stock:

  • 1. According to Zacks Investment Research, "RedHill Biopharma focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases, including cancer. RedHill's proprietary pipeline includes: RHB-105 - a combination therapy for H.pylori infection; RHB-104 - a combination therapy for Crohn's disease and multiple sclerosis; BEKINDA - a once-daily oral formulation of ondansetron for acute gastroenteritis and IBS-D; RHB-106 - an encapsulated formulation for bowel preparation licensed to Salix Pharmaceuticals; YELIVA - an orally-administered first-in-class SK2 selective inhibitor targeting oncology, inflammatory and gastrointestinal indications; MESUPRON - a uPA inhibitor targeting gastrointestinal and other solid tumors; RP101 - currently subject to an option-to-acquire, Hsp27 inhibitor targeting gastrointestinal cancers; RIZAPORT - an oral thin film formulation of rizatriptan for acute migraines. " (7/5/2017)
  • 2. FBR & Co analysts commented, "BeiGene presented updated data at ICML from BTK inhibitor BGB-3111’s clinical." (6/16/2017)

Who are some of Redhill Biopharma's key competitors?

Who are Redhill Biopharma's key executives?

Redhill Biopharma's management team includes the folowing people:

  • Dror Ben-Asher, Chairman of the Board, Chief Executive Officer
  • Micha Ben Chorin, Chief Financial Officer
  • Gilead Raday, Chief Operating Officer
  • Reza Fathi, Senior Vice President - Research & Development
  • Adi Frish, Senior Vice President - Business Development and Licensing
  • Uri Hananel Aharon, Chief Accounting Officer
  • Patricia Anderson, Vice President - Regulatory Affairs
  • Aida Bibliowicz, Vice President - Clinical Affairs Europe
  • Shani Maurice, Vice President - Business Development & Communications
  • Danielle T. Abramson Ph.D., Director - Intellectual Property & Research

How do I buy Redhill Biopharma stock?

Shares of Redhill Biopharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Redhill Biopharma's stock price today?

One share of Redhill Biopharma stock can currently be purchased for approximately $9.37.


MarketBeat Community Rating for Redhill Biopharma (NASDAQ RDHL)
Community Ranking:  3.6 out of 5 (  )
Outperform Votes:  158 (Vote Outperform)
Underperform Votes:  61 (Vote Underperform)
Total Votes:  219
MarketBeat's community ratings are surveys of what our community members think about Redhill Biopharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Redhill Biopharma (NASDAQ:RDHL) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $28.00 (198.83% upside)

Analysts' Ratings History for Redhill Biopharma (NASDAQ:RDHL)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/16/2017FBR & CoReiterated RatingBuyLowView Rating Details
6/15/2017HC WainwrightSet Price TargetBuy$33.00LowView Rating Details
5/4/2017Roth CapitalSet Price TargetBuy$26.00LowView Rating Details
3/29/2016NomuraReiterated RatingBuyN/AView Rating Details
11/11/2015Ascendiant Capital MarketsLower Price TargetBuy$28.00 -> $26.00N/AView Rating Details
9/29/2015Northland SecuritiesInitiated CoverageBuy$25.00N/AView Rating Details
(Data available from 7/23/2015 forward)

Earnings

Earnings History for Redhill Biopharma (NASDAQ:RDHL)
Earnings by Quarter for Redhill Biopharma (NASDAQ:RDHL)
Earnings History by Quarter for Redhill Biopharma (NASDAQ RDHL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/20173/31/2017($0.64)($0.50)ViewN/AView Earnings Details
7/27/2016Q116($0.58)($0.06)ViewListenView Earnings Details
2/25/2016Q1($0.48)$0.04$0.05 millionViewListenView Earnings Details
11/9/2015Q315($0.51)($0.04)ViewN/AView Earnings Details
7/29/2015Q215($0.49)($0.07)ViewListenView Earnings Details
4/30/2015Q115($0.56)($0.50)ViewN/AView Earnings Details
2/26/2015Q414($0.60)$0.06ViewN/AView Earnings Details
11/10/2014($0.61)($0.50)ViewN/AView Earnings Details
7/24/2014($0.38)($0.52)ViewN/AView Earnings Details
6/6/2014($0.44)$0.39ViewN/AView Earnings Details
4/30/2014($0.44)$0.39$7.01 millionViewN/AView Earnings Details
11/12/2013Q3 13($0.62)($0.04)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Redhill Biopharma (NASDAQ:RDHL)
2017 EPS Consensus Estimate: ($0.88)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.65)($0.65)($0.65)
Q2 20171($0.51)($0.51)($0.51)
Q3 20171($0.51)($0.51)($0.51)
Q4 20171$0.79$0.79$0.79
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Redhill Biopharma (NASDAQ:RDHL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Redhill Biopharma (NASDAQ:RDHL)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Redhill Biopharma (NASDAQ:RDHL)
Latest Headlines for Redhill Biopharma (NASDAQ:RDHL)
Source:
DateHeadline
seekingalpha.com logo3 Things In Biotech You Should Learn Today: July 20, 2017
seekingalpha.com - July 21 at 6:35 AM
streetinsider.com logoRedHill Biopharma (RDHL) Reports Last Patient Visit in BEKINDA Phase II Study for IBS-D - StreetInsider.com
www.streetinsider.com - July 17 at 8:29 AM
finance.yahoo.com logoRedHill Biopharma Announces Last Patient Visit in BEKINDA® Phase II Study for IBS-D
finance.yahoo.com - July 17 at 8:29 AM
americanbankingnews.com logo$340,000.00 in Sales Expected for Redhill Biopharma Ltd. (RDHL) This Quarter
www.americanbankingnews.com - July 14 at 12:04 PM
streetinsider.com logoRedHill Biopharma (RDHL) Expects DSMB RHB-104 Phase III Study Meeting in Late July - StreetInsider.com
www.streetinsider.com - July 13 at 8:17 PM
finance.yahoo.com logoRedHill Biopharma Announces Expected Timeline for DSMB meeting and Provides Update on Enrollment in the RHB-104 Phase III Study for Crohn's Disease
finance.yahoo.com - July 13 at 8:35 AM
americanbankingnews.com logo Analysts Expect Redhill Biopharma Ltd. (RDHL) to Post -$0.58 EPS
www.americanbankingnews.com - July 12 at 4:16 PM
americanbankingnews.com logoRedhill Biopharma Ltd. (RDHL) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - July 9 at 7:52 PM
seekingalpha.com logoQ3 Biotech Catalyst Watch: Phase 3 Data Releases (Part 2) - Seeking Alpha
seekingalpha.com - July 6 at 4:39 PM
americanbankingnews.com logoRedhill Biopharma Ltd. (NASDAQ:RDHL) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - July 4 at 7:24 AM
finance.yahoo.com logoRedHill Biopharma to Host Conference Call on Successful Phase III Top-Line Results with BEKINDA® for Acute Gastroenteritis
finance.yahoo.com - June 19 at 10:07 AM
americanbankingnews.com logo-$0.58 EPS Expected for Redhill Biopharma Ltd. (RDHL) This Quarter
www.americanbankingnews.com - June 16 at 6:06 PM
americanbankingnews.com logoRedhill Biopharma Ltd. (RDHL) Stock Rating Reaffirmed by FBR & Co
www.americanbankingnews.com - June 16 at 4:22 PM
streetinsider.com logoRedHill Biopharma (RDHL) Initiates Confirmatory Phase III Study with RHB-105 for H. pylori Infection
www.streetinsider.com - June 15 at 9:44 PM
streetinsider.com logoRedHill Biopharma (RDHL) Initiates Confirmatory Phase III Study ... - StreetInsider.com
www.streetinsider.com - June 15 at 4:43 PM
finance.yahoo.com logoRedHill Biopharma Announces Confirmatory Phase III Study Initiated with RHB-105 (TALICIA™) for H. pylori Infection
finance.yahoo.com - June 15 at 4:42 PM
finance.yahoo.com logoRedHill Biopharma Announces Confirmatory Phase III Study Initiated with RHB-105 (TALICIA(TM)) for H. pylori Infection
finance.yahoo.com - June 15 at 4:42 PM
benzinga.com logoRedHill Biopharma Higher Off Positive Phase III Results For BEKINDA
www.benzinga.com - June 15 at 12:03 AM
streetinsider.com logoRedHill Biopharma (RDHL) Phase 3 Study of BEKINDA to Treat Gastroenteritis and Gastritis Meets Primary Endpoint
www.streetinsider.com - June 15 at 12:03 AM
rttnews.com logoRedHill Biopharma Ltd. (RDHL) Is Up Sharply On Phase 3 Study Results
www.rttnews.com - June 15 at 12:03 AM
streetinsider.com logoRedHill Biopharma (RDHL) Phase 3 Study of BEKINDA to Treat Gastroenteritis and Gastritis Meets Primary Endpoint - StreetInsider.com
www.streetinsider.com - June 14 at 8:32 AM
finance.yahoo.com logoRedHill Biopharma Announces Successful Phase III Top-Line Results with BEKINDA® for Acute Gastroenteritis
finance.yahoo.com - June 14 at 8:32 AM
bizjournals.com logoWith former Salix team in tow, biopharma company expands in Raleigh
www.bizjournals.com - June 13 at 7:33 PM
finance.yahoo.com logoConcordia International Corp. Announces RedHill Biopharma Has Started Promoting Donnatal® in the U.S.
finance.yahoo.com - June 13 at 10:06 AM
finance.yahoo.com logoRedHill Biopharma Initiates Promotion of Donnatal® and EnteraGam® in the U.S.
finance.yahoo.com - June 13 at 10:06 AM
globenewswire.com logoRedHill Biopharma to Present at the 2017 BIO International Convention - GlobeNewswire (press release)
globenewswire.com - June 6 at 8:54 PM
benzinga.com logoExclusive: RedHill BioPharma CEO Talks Steering His Company Through A Year Heavy With Potential Catalysts
www.benzinga.com - June 5 at 8:06 PM
americanbankingnews.com logoRedHill Biopharma Ltd - (RDHL) Sees Significant Growth in Short Interest
www.americanbankingnews.com - May 28 at 7:16 AM
americanbankingnews.com logoQ2 2017 EPS Estimates for RedHill Biopharma Ltd - Raised by FBR & Co (RDHL)
www.americanbankingnews.com - May 8 at 7:41 AM
americanbankingnews.com logoHC Wainwright Analysts Give RedHill Biopharma Ltd - (RDHL) a $33.00 Price Target
www.americanbankingnews.com - May 7 at 7:44 AM
americanbankingnews.com logoRoth Capital Analysts Give RedHill Biopharma Ltd - (RDHL) a $26.00 Price Target
www.americanbankingnews.com - May 7 at 7:44 AM
americanbankingnews.com logoRedHill Biopharma Ltd - (RDHL) Issues Quarterly Earnings Results, Beats Expectations By $0.14 EPS
www.americanbankingnews.com - May 5 at 11:53 PM
americanbankingnews.com logoRedHill Biopharma Ltd - (RDHL) Receives Daily News Impact Score of 0.31
www.americanbankingnews.com - May 5 at 10:35 PM
americanbankingnews.com logoRedHill Biopharma Ltd - (RDHL) to Post FY2019 Earnings of $3.16 Per Share, FBR & Co Forecasts
www.americanbankingnews.com - May 5 at 7:58 PM
finance.yahoo.com logoRedHill Biopharma Announces Poster Presentation of the Positive RHB-105 Phase III Results for H. pylori Infection at Digestive Disease Week 2017
finance.yahoo.com - May 4 at 8:38 AM
americanbankingnews.com logoRedHill Biopharma Ltd - (RDHL) Receives Daily Media Impact Score of -0.12
www.americanbankingnews.com - May 2 at 5:28 PM
americanbankingnews.com logoZacks: Analysts Expect RedHill Biopharma Ltd - (RDHL) to Announce -$0.64 EPS
www.americanbankingnews.com - April 28 at 6:06 PM
americanbankingnews.com logoRedHill Biopharma Ltd - (RDHL) Getting Positive News Coverage, Study Finds
www.americanbankingnews.com - April 28 at 12:44 AM
seekingalpha.com logoRedhill Biopharma (RDHL) R&D Day on BEKINDA (Acute Gastroenteritis and IBS-D) - Slideshow
seekingalpha.com - April 27 at 7:54 PM
finance.yahoo.com logoRedHill Biopharma to Host First Quarter 2017 Financial Results Conference Call on May 3, 2017
finance.yahoo.com - April 25 at 10:16 AM
streetinsider.com logoRedHill Biopharma (RDHL) Enrolls Last Patient in the BEKINDA Phase II Study for IBS-D
www.streetinsider.com - April 24 at 11:53 AM
finance.yahoo.com logoRedHill Biopharma Announces Enrollment of Last Patient in the BEKINDA® Phase II Study for IBS-D
finance.yahoo.com - April 24 at 11:53 AM
finance.yahoo.com logoRedHill Biopharma Announces Peer-Reviewed Publication of the Positive YELIVA® Phase I Study Results in Advanced Solid Tumors
finance.yahoo.com - April 20 at 8:38 AM
finance.yahoo.com logoRedHill Biopharma to Host R&D Day on BEKINDA® for Acute Gastroenteritis and IBS-D
finance.yahoo.com - April 19 at 9:37 AM
finance.yahoo.com logoRedHill Biopharma Receives Notice of Allowance for Two Additional U.S. Patents Covering BEKINDA® - Yahoo Finance
finance.yahoo.com - April 18 at 9:32 AM
finance.yahoo.com logoRedHill Biopharma Receives Notice of Allowance for Two Additional U.S. Patents Covering BEKINDA®
finance.yahoo.com - April 18 at 9:32 AM
streetinsider.com logoRedHill Biopharma (RDHL) & IntelGenx Awarded Marketing Approval of RIZAPORT® for Migraines in Luxembourg - StreetInsider.com
www.streetinsider.com - April 15 at 8:34 AM
finance.yahoo.com logoRedHill Biopharma and IntelGenx Announce Marketing Approval of RIZAPORT® for Migraines in Luxembourg
finance.yahoo.com - April 13 at 9:46 AM
finance.yahoo.com logoRedHill Biopharma Announces Exclusive U.S. License from Entera Health for Commercial GI Product EnteraGam®
finance.yahoo.com - April 7 at 7:51 PM
americanbankingnews.com logo Analysts Expect RedHill Biopharma Ltd - (RDHL) Will Announce Earnings of -$0.64 Per Share
www.americanbankingnews.com - April 7 at 6:51 PM

Social

Chart

Redhill Biopharma (RDHL) Chart for Sunday, July, 23, 2017

This page was last updated on 7/23/2017 by MarketBeat.com Staff